Findings from a multi-center, international clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes.
Drugmaker Novo Nordisk announced that the treatment reduced the risk of heart attacks and strokes by a fifth in August, illustrating the treatment s benefits beyond weight loss .
Wegovy was found to cut the risk of serious heart events by 20% Novo Nordisk has now asked the U.S. FDA to reflect the heart benefits in the drug's label.
London, November 13 (IANS): Novo Nordisk's obesity drug semaglutide (marketed as Wegovy) can significantly reduce risk of major adverse cardiovascular events (MACE) by 20 per cent in adults with established cardiovascular disease (CVD) and overweight or o
Ozempic-Like Drug Wegovy Reduces Heart Attack, Stroke Risk By 20% today.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from today.com Daily Mail and Mail on Sunday newspapers.